Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.
1. A method for treatment of cervical or vaginal cancer or their associated cervical intraepithelial neoplasia I-III (CINI-III) and vaginal intraepithelial neoplasia I-III (VINI-III)), comprising
administering an effective amount of an estrogen antagonist therapy to a human patient having cervical intraepithelial neoplasia (CINI-III) and vaginal intraepithelial neoplasia I-III (VINI-III), wherein the estrogen antagonist therapy is a selective estrogen receptor modulator that has estrogen receptor-antagonistic effects and does not have receptor-agonist effects in cervical or vaginal tissue and that is effective to decrease cancer lesion size, reduce, resolve, or halt progression or reoccurrence of the cancerous or precancerous lesions thereof, thereby treating the cervical intraepithelial neoplasia (CINI-III) and vaginal intraepithelial neoplasia I-III (VINI-III).
2. The method of claim 1 wherein the estrogen antagonist therapy is fulvestrant.
3. The method of claim 2 wherein the estrogen antagonist therapy is administered at a loading dose of 500 mg (±10%) on day 1 and 14 and monthly dosing of either 250 mg (±10%) or 500 mg (±10%).
4. The method of claim 1 wherein the estrogen antagonist therapy is raloxifene.